Evidence map›Paper›PMID 34875040›Full record

ArticleRheumatology (Oxford, England)2022

Screening for preclinical parenchymal lung disease in rheumatoid arthritis.

Anthony J Esposito, Jeffrey A Sparks, Ritu R Gill, Hiroto Hatabu, Eric J Schmidlin, Partha V Hota, Sergio Poli, Elaine A Fletcher, Wesley Xiong, Michelle L Frits and 9 more

Open access · greenAbstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Article
  6. Observational
  7. Global epidemiology and burden of interstitial lung disease.The Lancet. Respiratory medicine · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Heterogeneity in rheumatoid arthritis-associated interstitial lung disease: time for splitting?Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2023
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Anthony J EspositoDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.ORCID 0000-0002-8636-0845
Jeffrey A SparksDepartment of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital.ORCID 0000-0002-5556-4618
Ritu R GillDepartment of Radiology, Beth Israel Deaconess Medical Center.
Hiroto HatabuDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Eric J SchmidlinDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Partha V HotaDepartment of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Sergio PoliDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Elaine A FletcherDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Wesley XiongDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Michelle L FritsDepartment of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital.
Christine K IannacconeDepartment of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital.
Maria PradoDepartment of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital.
Alessandra ZaccardelliDepartment of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital.
Allison MarshallDepartment of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital.
Paul F DellaripaDepartment of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital.
Michael E WeinblattDepartment of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital.
Nancy A ShadickDepartment of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital.
Ivan O RosasDepartment of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston, TX, USA.
Tracy J DoyleDepartment of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Brigham and Women's Hospital · USBaylor College of Medicine · USHadassah Medical Center · ILNorthwestern University · US

Funding

The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2M
Clinical Genetics and Screening for Pulmonary FibrosisR01HL130974 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GARY MATTHEW HUNNINGHAKE, Benjamin Alexander Raby · 2016 to 2026
$10.0M
Genetic and Genomic Characterization of the Occurrence and Progression of Interstitial Lung AbnormalitiesR01HL135142 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MICHAEL H. CHO, GARY MATTHEW HUNNINGHAKE · 2017 to 2026
$7.7M
Interstitial Lung Abnormalities: Defining the Phenotype, Causes, and Consequences.R01HL111024 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNNINGHAKE, GARY MATTHEW · 2013 to 2022
$6.4M
Rheumatoid Arthritis-associated Parenchymal Lung Disease: Clinical and Molecular PhenotypesR01HL155522 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Jeffrey Andrew Sparks, George R Washko · 2022 to 2026
$3.5M
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatmentR01CA203636 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI NISHINO, MIZUKI · 2017 to 2021
$2.9M
Rheumatoid Arthritis and Respiratory Outcomes in Prospective CohortsK23AR069688 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SPARKS, JEFFREY ANDREW · 2016 to 2020
$766k
Clinical and Molecular Characteristics of Rheumatoid Arthritis-associated ILDK23HL119558 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DOYLE, TRACY JENNIFER · 2015 to 2018
$763k
Respiratory Diseases, Genetics, and Rheumatoid Arthritis RiskR03AR075886 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SPARKS, JEFFREY ANDREW · 2019 to 2020
$179k
Molecular and Genetic Characteristics of Progressive Rheumatoid Arthritis-associated Interstitial Lung DiseaseR03HL148484 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI DOYLE, TRACY JENNIFER · 2019 to 2020
$134k
PAD4 Contributes to the Profibrotic Phenotype of Fibroblasts from Patients with IPF and Promotes Lung FibrosisF32HL151132 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ESPOSITO, ANTHONY JOSEPH · 2020 to 2021
$103k
NCI NIH HHS R01 CA203636NCI NIH HHS U01 CA209414NHLBI NIH HHS F32 HL151132NHLBI NIH HHS K23 HL119558NHLBI NIH HHS L30 HL149048NHLBI NIH HHS R01 HL111024NHLBI NIH HHS R01 HL130974NHLBI NIH HHS R01 HL135142NHLBI NIH HHS R01 HL155522NHLBI NIH HHS R03 HL148484NIAMS NIH HHS K23 AR069688NIAMS NIH HHS R03 AR075886
6 · The paper itself

Abstract

objectivesPulmonary disease is a common extraarticular manifestation of RA associated with increased morbidity and mortality. No current strategies exist for screening this at-risk population for parenchymal lung disease, including emphysema and interstitial lung disease (ILD).

methodsRA patients without a diagnosis of ILD or chronic obstructive pulmonary disease underwent prospective and comprehensive clinical, laboratory, functional and radiological evaluations. High resolution CT (HRCT) scans were scored for preclinical emphysema and preclinical ILD and evaluated for other abnormalities.

resultsPulmonary imaging and/or functional abnormalities were identified in 78 (74%) of 106 subjects; 45% had preclinical parenchymal lung disease. These individuals were older with lower diffusion capacity but had similar smoking histories compared with no disease. Preclinical emphysema (36%), the most commonly detected abnormality, was associated with older age, higher anti-cyclic citrullinated peptide antibody titres and diffusion abnormalities. A significant proportion of preclinical emphysema occurred among never smokers (47%) with a predominantly panlobular pattern. Preclinical ILD (15%) was not associated with clinical, laboratory or functional measures.

conclusionWe identified a high prevalence of undiagnosed preclinical parenchymal lung disease in RA driven primarily by isolated emphysema, suggesting that it may be a prevalent and previously unrecognized pulmonary manifestation of RA, even among never smokers. As clinical, laboratory and functional evaluations did not adequately identify preclinical parenchymal abnormalities, HRCT may be the most effective screening modality currently available for patients with RA.

Indexed as

Arthritis, RheumatoidEmphysemaLung Diseases, InterstitialHumansLungProspective Studiesemphysemaepidemiologyinterstitial lung diseasepreclinicalrheumatoid arthritisscreening

Identifiers

PMID34875040
PMCPMC9348774
OpenAlexW4200249031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.